Hi-Great Group Holding Company

Equities

HIGR

US4283711087

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:40:02 18/10/2022 BST			5-day change	1st Jan Change
0.0178 ^USD	-98.22%		-.--%	-.--%

2023	Hi-Great Group Holding Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Hi-Great Group Holding Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Hi-Great Group Holding Company Reports Earnings Results for the First Quarter Ended March 31, 2023

May 19, 2023 at 11:12 am

Hi-Great Group Holding Company reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was USD 0.017269 million compared to USD 0.060918 million a year ago. Net loss was USD 0.012118 million compared to net income of USD 0.029243 million a year ago.

Latest news about Hi-Great Group Holding Company

Hi-Great Group Holding Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Hi-Great Group Holding Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Hi-Great Group Holding Company Reports Earnings Results for the First Quarter Ended March 31, 2023	19/05/23	CI
Hi-Great Group Holding Company Reports Earnings Results for the Full Year Ended December 31, 2022	17/04/23	CI
Hi-Great Group Holding Company Auditor Raises 'Going Concern' Doubt	16/04/23	CI
Hi-Great Group Holding Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Hi-Great Group Holding Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	06/09/22	CI
Hi-Great Group Holding Company Reports Earnings Results for the First Quarter Ended March 31, 2022	01/08/22	CI
Hi-Great Group Holding Company Reports Earnings Results for the Full Year Ended December 31, 2021	12/07/22	CI
Hi-Great Group Holding Company Auditor Raises 'Going Concern' Doubt	11/07/22	CI
Hi-Great Group Holding Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	09/05/22	CI
Hi-Great Group Holding Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2021	02/05/22	CI
Hi-Great Group Holding Company Auditor Raises 'Going Concern' Doubt	23/02/22	CI

Chart Hi-Great Group Holding Company

Duration

Period

More charts

Company Profile

Hi-Great Group Holding Company holds a license agreement for New Business Plan with the KRAS gene, which is among the most frequently mutated genes across all cancers, including pancreatic, lung, and colorectal. The Company is engaged in marketing, selling, and distributing SellaCare, Inc's organic longevity health supplement. The Company is in license agreement with SellaCare, Inc. in the areas of longevity and additional health benefits and it also expands into the cosmetic sector as an overall sustainable revenue platform.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HI-GREAT GROUP HOLDING COMPANY	-.--%	1.78M
MODERNA, INC.	+29.77%	49.46B
IQVIA HOLDINGS INC.	+1.00%	42.58B
LONZA GROUP AG	+50.24%	42.49B
CELLTRION, INC.	-5.26%	29.09B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.64B
BIO-TECHNE CORPORATION	+8.22%	13.16B
MEDPACE HOLDINGS, INC.	+32.41%	12.55B
UNITED THERAPEUTICS CORPORATION	+24.01%	12.1B

Other Biotechnology & Medical Research